+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study



Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study



Journal of Bone and Mineral Research 30(2): 232-239



Proton pump inhibitors (PPIs) have been associated with diminished bone mineral density (BMD) and an increased risk of fracture; however, prior studies have not yielded consistent results, and many have suboptimal ascertainment of both PPI use and BMD. We used data from the Study of Women's Health Across the Nation (SWAN), a multicenter, multi-ethnic, community-based longitudinal cohort study of women across the menopause transition to examine the association between annualized BMD changes and new use of PPIs. We compared changes in BMD in new PPI users with changes in BMD in new users of histamine 2 receptor antagonists (H2RAs) and with changes in BMD in subjects who did not use either class of medications. Mixed linear regression models included recognized risk factors for osteoporosis, including demographics, menopausal transition stage, body mass index (BMI), lifestyle factors, as well as comorbidities and concomitant medications. To provide further evidence for the validity of our analytic approach, we also examined the effects of hormone-replacement therapy (HT), a class of medications that should reduce bone loss, on changes in BMD as an internal positive control group. We identified 207 new users of PPIs, 185 new users of H2RAs, and 1,676 non-users. Study subjects had a mean age of 50 years and were followed for a median of 9.9 years. Adjusted models found no difference in the annualized BMD change at the lumbar spine, femoral neck, or total hip in PPI users compared with H2RA users or non-users. These results were robust to sensitivity analyses. BMD increased as expected in HT users, supporting the validity of our study design. These longitudinal analyses plus similar prior studies argue against an association between PPI use and BMD loss.

(PDF emailed within 0-6 h: $19.90)

Accession: 051845594

Download citation: RISBibTeXText

PMID: 25156141

DOI: 10.1002/jbmr.2344


Related references

Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study. Osteoporosis International 27(3): 1181-1189, 2016

Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists. Current Medical Research and Opinion 34(4): 577-583, 2017

Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study. Current Medical Research and Opinion 33(12): 2251-2259, 2017

Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study. Current Medical Research and Opinion 33(12): 2201-2209, 2017

Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evidence-Based Medicine 18(5): 192-193, 2014

Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. Plos One 14(5): E0216750, 2019

Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of Bone and Mineral Research 27(1): 111-118, 2013

Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study. Journal of Digestive Diseases 18(3): 143-150, 2017

Prevention of stress induced ulcers: histamine-2 receptor antagonists or proton pump inhibitors? - gastric hemorrhage occur more often under proton pump inhibitors. Deutsche Medizinische Wochenschrift 139(25-26): 1338, 2014

Proton pump inhibitors use and change in bone mineral density. International Journal of Rheumatic Diseases 19(9): 864-868, 2017

General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study. Bmc Family Practice 17: 57, 2017

Effect of long-term proton pump inhibitors on bone mineral density. La Tunisie Medicale 96(3): 193-197, 2018

Fracture risk and bone mineral density reduction associated with proton pump inhibitors. PharmacoTherapy 32(1): 67-79, 2012

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Current Rheumatology Reviews 12(2): 162-166, 2017

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Archives of Internal Medicine 170(9): 765-771, 2010